Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

British Journal of Cancer logoLink to British Journal of Cancer
. 1992 May;65(5):731–734. doi: 10.1038/bjc.1992.154

Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.

P A Pasanen 1, M Eskelinen 1, K Partanen 1, P Pikkarainen 1, I Penttilä 1, E Alhava 1
PMCID: PMC1977373  PMID: 1316775

Abstract

The aim of this study was to evaluate the new monoclonal tumour marker CA 242 in the diagnosis of pancreatic carcinoma and to compare it with the established markers CA 50 and CEA. Serum concentrations were determined in 113 patients with jaundice, in 20 patients with laboratory values suggesting cholestasis, and in 60 patients with a suspicion to have chronic pancreatitis. Twenty-four of these 193 patients had pancreatic carcinoma and two patients had carcinoma of papilla of Vater. The sensitivities of CA 242, CA 50 and CEA were 80.7%, 96.1%, and 92.3%, respectively. The specificities were 79.0%, 58.0%, and 59.2%. The sensitivities of combinations of CA 50 and CEA with CA 242 did not exceed the sensitivity of CA 50 alone. The specificity of CA 242 was improved by combining it with CEA (92.2%). The serum marker CA 242 seems to be less sensitive than CEA and CA 50 in the detection of pancreatic carcinoma, but it may prove useful because of its high specificity.

Full text

PDF
731

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Begent R. H. The value of carcinoembryonic antigen measurement in clinical practice. Ann Clin Biochem. 1984 Jul;21(Pt 4):231–238. doi: 10.1177/000456328402100401. [DOI] [PubMed] [Google Scholar]
  2. Carr-Locke D. L. Serum and pancreatic juice carcinoembryonic antigen in pancreatic and biliary disease. Gut. 1980 Aug;21(8):656–661. doi: 10.1136/gut.21.8.656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eskelinen M., Lipponen P., Marin S., Haapasalo H., Mäkinen K., Ahtola H., Puittinen J., Nuutinen P., Alhava E. Prognostic factors in human pancreatic cancer, with special reference to quantitative histology. Scand J Gastroenterol. 1991 May;26(5):483–490. doi: 10.3109/00365529108998570. [DOI] [PubMed] [Google Scholar]
  4. Habib N. A., Hershman M. J., Haberland F., Papp L., Wood C. B., Williamson R. C. The use of CA-50 radioimmunoassay in differentiating benign and malignant pancreatic disease. Br J Cancer. 1986 May;53(5):697–699. doi: 10.1038/bjc.1986.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Habib N. A., Hershman M. J., Papp L., Swift I., Williamson R. C., Wood C. B. The detection of colorectal carcinomas with the use of CA-50 radioimmunoassay inhibition test. Int J Colorectal Dis. 1986 Jul;1(3):186–187. doi: 10.1007/BF01648448. [DOI] [PubMed] [Google Scholar]
  6. Habib N. A., Hershman M. J., Smadja C., Wood C. B. The use of CA-50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant liver diseases. Br J Surg. 1986 Sep;73(9):758–759. doi: 10.1002/bjs.1800730927. [DOI] [PubMed] [Google Scholar]
  7. Haglund C., Lindgren J., Roberts P. J., Kuusela P., Nordling S. Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer. 1989 Dec;60(6):845–851. doi: 10.1038/bjc.1989.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Haglund C., Roberts P. J., Kuusela P., Scheinin T. M., Mäkelä O., Jalanko H. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer. 1986 Feb;53(2):197–202. doi: 10.1038/bjc.1986.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hansen H. J., Snyder J. J., Miller E., Vandevoorde J. P., Miller O. N., Hines L. R., Burns J. J. Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. Hum Pathol. 1974 Mar;5(2):139–147. doi: 10.1016/s0046-8177(74)80061-4. [DOI] [PubMed] [Google Scholar]
  10. Holmgren J., Lindholm L., Persson B., Lagergård T., Nilsson O., Svennerholm L., Rudenstam C. M., Unsgaard B., Yngvason F., Pettersson S. Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. Br Med J (Clin Res Ed) 1984 May 19;288(6429):1479–1482. doi: 10.1136/bmj.288.6429.1479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kalser M. H., Barkin J. S., Redlhammer D., Heal A. Circulating carcinoembryonic antigen in pancreatic carcinoma. Cancer. 1978 Sep;42(3 Suppl):1468–1471. doi: 10.1002/1097-0142(197809)42:3+<1468::aid-cncr2820420816>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  12. Kuusela P., Haglund C., Roberts P. J. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer. 1991 Apr;63(4):636–640. doi: 10.1038/bjc.1991.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lindholm L., Holmgren J., Svennerholm L., Fredman P., Nilsson O., Persson B., Myrvold H., Lagergård T. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol. 1983;71(2):178–181. doi: 10.1159/000233384. [DOI] [PubMed] [Google Scholar]
  14. Longmire W. P., Jr Cancer of the pancreas: palliative operation, Whipple procedure, or total pancreatectomy. World J Surg. 1984 Dec;8(6):872–879. doi: 10.1007/BF01656027. [DOI] [PubMed] [Google Scholar]
  15. Roberts P. J. The clinical value of tumour markers. Ann Chir Gynaecol. 1986;75(5):247–248. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES